UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13D

 

 Under the Securities Exchange Act of 1934

 

(Amendment No. 5)*

 

Achillion Pharmaceuticals, Inc.

(Name of Issuer)

 

Common Stock, $0.001 par value per share

(Title of Class of Securities)

 

00448Q201

(CUSIP Number)

 

RA Capital Management, LLC

20 Park Plaza, Suite 1200

Boston, MA 02116

Telephone: 617.778.2512

Attn: Peter Kolchinsky

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications) 

 

September 30, 2013

(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. x

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 
 

 

CUSIP No. 00448Q201

 

1

Names of Reporting Persons.

 

RA Capital Healthcare Fund, L.P.

 

2 Check the Appropriate Box if a Member of a Group (See Instructions)
  (a) ¨
  (b) ¨
3 SEC Use Only
4

Source of Funds (See Instructions):

WC

 

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e):

¨

 

6

Citizenship or Place of Organization. Delaware

 

Number

of Shares

Beneficially

Owned by

Each

Reporting

Person With

7   Sole Voting Power 0 shares

 

8   Shared Voting Power 15,301,555 shares*

 

9 Sole Dispositive Power 0 shares

 

10 Shared Dispositive Power 15,301,555 shares*

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person

15,301,555 shares*

 

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)      ¨
13

Percent of Class Represented by Amount in Row (11)

15.83%*

 

14

Type of Reporting Person (See Instructions)

PN (Limited Partnership)

 

 

*Reflects the number of shares of outstanding common stock of the issuer beneficially owned by the Reporting Person on September 30, 2013. The percentage of the outstanding common stock beneficially owned was calculated based upon 96,642,564 shares outstanding according to the Quarterly Report on Form 10-Q filed by the Issuer on August 7, 2013.

 

 

2
 

CUSIP No. 00448Q201

 

1

Names of Reporting Persons.

 

RA Capital Management, LLC

 

2 Check the Appropriate Box if a Member of a Group (See Instructions)
  (a) ¨
  (b) ¨
3 SEC Use Only
4

Source of Funds (See Instructions):

AF

 

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e):

¨

 

6

Citizenship or Place of Organization. Massachusetts

 

Number

of Shares

Beneficially

Owned by

Each

Reporting

Person With

7   Sole Voting Power 0 shares

 

8   Shared Voting Power 19,957,061 shares*

 

9 Sole Dispositive Power 0 shares

 

10 Shared Dispositive Power 19,957,061 shares*

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person

19,957,061 shares*

 

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)      ¨
13

Percent of Class Represented by Amount in Row (11)

20.65%*

 

14

Type of Reporting Person (See Instructions)

IA, OO (Limited Liability Company)

 

 

*Reflects the number of shares of outstanding common stock of the issuer beneficially owned by the Reporting Person on September 30, 2013. The percentage of the outstanding common stock beneficially owned was calculated based upon 96,642,564 shares outstanding according to the Quarterly Report on Form 10-Q filed by the Issuer on August 7, 2013.

 

3
 

 

CUSIP No. 00448Q201

 

1

Names of Reporting Persons.

 

Peter Kolchinsky

 

2 Check the Appropriate Box if a Member of a Group (See Instructions)
  (a) ¨
  (b) ¨
3 SEC Use Only
4

Source of Funds (See Instructions):

AF

 

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e):

¨

 

6

Citizenship or Place of Organization. United States

 

 

Number

of Shares

Beneficially

Owned by

Each

Reporting

Person With

7   Sole Voting Power 0 shares

 

8   Shared Voting Power 19,957,061 shares*

 

9 Sole Dispositive Power 0 shares

 

10 Shared Dispositive Power 19,957,061 shares*

 

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person

19,957,061 shares

 

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)      ¨
13

Percent of Class Represented by Amount in Row (11)

20.65%*

 

14

Type of Reporting Person (See Instructions)

HC, IN

 

 

*Reflects the number of shares of outstanding common stock of the issuer beneficially owned by the Reporting Person on September 30, 2013. The percentage of the outstanding common stock beneficially owned was calculated based upon 96,642,564 shares outstanding according to the Quarterly Report on Form 10-Q filed by the Issuer on August 7, 2013.

 

4
 

 

EXPLANATORY NOTE

 

This Amendment No. 5 amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”) on November 1, 2013 (the “Original Statement”), as amended by Amendment No. 1 to Schedule 13D filed with the SEC on March 21, 2014, Amendment No. 2 to Schedule 13D filed with the SEC on June 24, 2014, Amendment No. 3 to Schedule 13D filed with the SEC on August 20, 2014, and Amendment No. 4 to Schedule 13D filed with the SEC on August 27, 2014 (collectively, the “Statement”), in each case filed by the Reporting Persons (defined below) with respect to the common stock, par value $0.001 per share (“Common Stock”), of Achillion Pharmaceuticals, Inc. (the “Issuer”).

 

RA Capital Management, LLC (“Capital”) is the general partner of RA Capital Healthcare Fund, L.P. (the “Fund”) and serves as investment adviser for a separately managed account (the “Account”). Peter Kolchinsky is the manager of Capital. Mr. Kolchinsky, Capital and the Fund are referred to herein collectively as the “Reporting Persons.” Shares reported herein as beneficially owned by the Fund represent shares of Common Stock (i) held of record by the Fund and (ii) issuable upon exercise of call options held of record by the Fund. Shares reported herein as beneficially owned by Capital and Mr. Kolchinsky represent (a) the above-referenced shares of Common Stock beneficially owned by the Fund and (b) shares of Common Stock (I) held in the Account, and (II) issuable upon exercise of call options held in the Account. Shares of Common Stock, including Common Stock underlying call options, reported herein are reported as beneficially owned for purposes of Section 13(d) of the Securities Exchange Act of 1934, and the inclusion of such shares in this Amendment shall not be deemed an admission that the Reporting Persons are beneficial owners of such shares for any other purpose.

 

This Amendment is being filed to report the Reporting Persons’ holdings of Common Stock (1) as of September 30, 2013, the first date on which any Reporting Person could be deemed to have beneficially owned more than 20% of the outstanding shares of the Common Stock, and (2) except to the extent previously reported in this Statement, on each date thereafter on which the number of shares of the outstanding Common Stock beneficially owned by any Reporting Person increased or decreased by an amount equal to or exceeding one percent of the class outstanding (each, a “Subsequent Amendment Date”). Information regarding the holdings of each Reporting Person as of September 30, 2013 is set forth on the cover page hereto, and information regarding each Reporting Person’s holdings as of each Subsequent Amendment Date is set forth in Item 5 hereof. In addition, this Amendment is being filed to amend and supplement Items 5 and 6 of the Statement.

 

Unless otherwise stated herein, the information provided in this Amendment speaks as of the dates of the transactions and events reported herein, and does not update the Statement through the date of the filing of this Amendment or any other date. This Amendment covers the period commencing on September 30, 2013 and ending on November 20, 2013 (the last previously unreported Subsequent Amendment Date). The Reporting Persons became eligible to report, and have commenced reporting, on Schedule 13G as of August 28, 2014.

 

Item 5. Interest in Securities of the Issuer

 

Item 5 of the Statement is hereby amended and supplemented as follows:

 

(a)-(b) The table below sets forth (1) the number of shares of Common Stock beneficially owned by each of the Reporting Persons as of September 30, 2013 and as of each Subsequent Amendment Date and (2) the percentage of the outstanding Common Stock beneficially owned by each of the Reporting Persons as of each such date, calculated based upon the total number of shares outstanding reported in the most recent Quarterly Report on Form 10-Q filed by the Issuer prior to the applicable date.

 

  RA Capital Healthcare Fund, L.P. RA Capital Management, LLC (1) Peter Kolchinsky (1)
Date (#) (%) (#) (%) (#) (%)
9/30/13 15,301,555 15.83% 19,957,061 20.65% 19,957,061 20.65%
10/11/13 17,359,300 17.96% 22,405,771 23.18% 22,405,771 23.18%
10/14/13 19,219,145 19.89% 24,775,000 25.64% 24,775,000 25.64%
10/31/13 20,150,164 20.85% 25,961,007 28.86% 25,961,007 28.86%
11/12/13 21,568,214 22.31% 27,756,007 28.71% 27,756,007 28.71%
11/20/13 22,445,115 23.22% 28,866,007 29.86% 28,866,007 29.86%

 

(1)Amounts reported above for the Fund represent shares of Common Stock beneficially owned by the Fund. Amounts reported above for each of Capital and Peter Kolchinsky represent shares of Common Stock beneficially owned by the Fund and the Account.

 

5
 

 

 

 

(c) The following tables list the transactions in the Common Stock that were effected by the Fund and the Account during the sixty day period prior to September 30, 2013 and during the sixty day period prior to each Subsequent Amendment Date, excluding transactions previously reported in this Statement. Each of the transactions listed below was an open market purchase or sale of Common Stock.

 

Fund Transactions

 

Transaction Purchase / Sale Date Shares (#) Price ($)
Purchase 7/1/2013         39,400 6.5000
Purchase 7/2/2013       145,613 6.4835
Purchase 7/2/2013       128,027 6.5150
Purchase 7/2/2013       151,758 6.5050
Purchase 7/2/2013         38,402 6.4550
Purchase 7/2/2013         93,839 6.3104
Purchase 7/2/2013       504,194 6.3986
Purchase 7/2/2013       160,590 6.4147
Purchase 7/2/2013       159,977 6.4944
Purchase 7/3/2013         38,400 6.2497
Purchase 7/8/2013         38,400 6.2877
Purchase 7/9/2013         76,800 6.3235
Purchase 7/17/2013         38,400 7.0934
Sale 7/19/2013  (38,400) 7.2125
Purchase 7/22/2013         24,883 7.1600
Purchase 7/22/2013         38,400 7.2311
  Sale 7/24/2013         (7,862) 7.2552
  Purchase 7/25/2013         37,250 7.1947
  Sale 7/25/2013  (14,592) 7.15
  Sale 7/25/2013  (40,829) 7.1948
  Purchase 7/29/2013         11,441 6.9
  Purchase 7/29/2013          6,453 6.905
  Sale 7/29/2013         (3,377) 6.9525
  Purchase 8/2/2013         23,100 6.9835
  Sale 8/5/2013  (23,100) 7.1141
Purchase 8/9/2013 77,000 6.3000
  Purchase 8/20/2013         38,500 6.7492
  Sale 8/20/2013         (9,951) 6.8643
  Sale 8/21/2013         (4,312) 6.8741
Purchase 8/21/2013         23,100 6.6922
Purchase 8/22/2013         52,652 6.7645
  Purchase 8/26/2013       115,500 6.575
  Purchase 8/26/2013         38,500 6.58
Purchase 8/27/2013         77,000 6.4850
Purchase 8/28/2013         38,500 6.3850

 

6
 

Account Transactions

 

Transaction Purchase / Sale Date Shares (#) Price ($)
Purchase 7/1/2013          11,600 6.5000
Purchase 7/2/2013          43,987 6.4835
Purchase 7/2/2013          38,673 6.5150
Purchase 7/2/2013          45,842 6.5050
Purchase 7/2/2013          11,598 6.4550
Purchase 7/2/2013          28,361 6.3104
Purchase 7/2/2013         152,306 6.3986
Purchase 7/2/2013          48,510 6.4147
Purchase 7/2/2013          48,323 6.4944
Purchase 7/3/2013          11,600 6.2497
Purchase 7/8/2013          11,600 6.2877
Purchase 7/9/2013          23,200 6.3235
  Sale 7/10/2013         (72,400) 6.335
  Sale 7/10/2013         (22,900) 6.405
  Sale 7/10/2013         (41,547) 6.4064
  Sale 7/11/2013       (288,153) 6.4504
  Sale 7/11/2013         (50,000) 6.472
Purchase 7/17/2013          11,600 7.0934
Sale 7/19/2013         (11,600) 7.2125
Purchase 7/22/2013            7,517 7.1600
Purchase 7/22/2013          11,600 7.2311
  Sale 7/24/2013           (2,375) 7.2552
  Purchase 7/25/2013          11,252 7.1947
  Sale 7/25/2013           (4,408) 7.15
  Sale 7/25/2013         (12,334) 7.1948
  Purchase 7/29/2013            3,459 6.9
  Purchase 7/29/2013            1,947 6.905
  Sale 7/29/2013         (64,000) 6.91
  Sale 7/29/2013           (1,020) 6.9525
  Purchase 8/2/2013            6,900 6.9835
  Sale 8/5/2013           (6,900) 7.1141
Purchase 8/9/2013          23,000 6.3000
  Purchase 8/20/2013          11,500 6.7492
  Sale 8/20/2013           (2,972) 6.8643
  Sale 8/21/2013           (1,288) 6.8741
Purchase 8/21/2013            6,900 6.6922
Purchase 8/22/2013          15,727 6.7645
  Purchase 8/26/2013          34,500 6.575
  Purchase 8/26/2013          11,500 6.58
Purchase 8/27/2013          23,000 6.4850
Purchase 8/28/2013          11,500 6.3850

 

7
 

See Item 6 below for information regarding call options that were purchased or sold by the Reporting Persons, as applicable, during the sixty day period prior to September 30, 2013 and the sixty day period prior to each Subsequent Amendment Date.

 

(d) Not applicable.

 

(e) Not applicable.

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

  

Item 6 of the Statement is hereby amended and supplemented as follows:

 

The following tables list call options for shares of Common Stock that were either purchased or sold by the Fund or the Account, as applicable, during the period covered by this Amendment, excluding any such options previously reported in this Statement. Each of the options listed below reflects an “option spread” strategy pursuant to which the Fund or the Account, as applicable, simultaneously (1) purchased call option contracts representing a right to purchase a specified number of shares of Common Stock and (2) sold call option contracts representing an obligation to sell an equal number of shares of Common Stock, in each case at the exercise price specified in the table below.  Each option contract represents either the right to buy or the obligation to sell 100 shares of the issuer’s common stock.

 

Fund Options

 

Option Contract Type Purchase / Sale Date Expiration Date No. Option Contracts Exercise Price

Call Option

(right to buy) (1)

5/31/13 1/18/14 7,435 $10.00

Call Option

(obligation to sell) (1)

5/31/13 1/18/14 7,435 $20.00

Call Option

(right to buy) (1)

6/12/13 1/18/14 7,450 $10.00

Call Option

(obligation to sell) (1)

6/12/13 1/18/14 7,450 $20.00

Call Option

(right to buy)

7/15/13 1/17/15 3,840 $7.50

Call Option

(obligation to sell)

7/15/13 1/17/15 3,840 $20.00

Call Option

(right to buy)

7/15/13 1/17/15 3,840 $7.50

Call Option

(obligation to sell)

7/15/13 1/17/15 3,840 $20.00

Call Option

(right to buy)

7/15/13 1/17/15 7,680 $7.50

Call Option

(obligation to sell)

7/15/13 1/17/15 7,680 $20.00

Call Option

(right to buy)

7/15/13 1/17/15 768 $7.50

Call Option

(obligation to sell)

7/15/13 1/17/15 768 $20.00

Call Option

(right to buy)

7/25/13 1/17/15 3,072 $7.50

Call Option

(obligation to sell)

7/25/13 1/17/15 3,072 $20.00

Call Option

(right to buy)

9/26/13 1/18/14 7,760 $7.50

Call Option

(obligation to sell)

9/26/13 1/18/14 7,760 $15.00
(1)These option contracts were cancelled on October 1, 2013, through the sale and purchase of options having identical terms, which closing transactions were previously reported in Amendments 3 and 4 to the Statement.

 

8
 

Account Options

 

Option Contract Type Purchase / Sale Date Expiration Date No. Option Contracts Exercise Price

Call Option

(right to buy) (2)

5/31/13 1/18/14 2,565 $10.00

Call Option

(obligation to sell) (2)

5/31/13 1/18/14 2,565 $20.00

Call Option

(right to buy) (2)

6/12/13 1/18/14 2,550 $10.00

Call Option

(obligation to sell) (2)

6/12/13 1/18/14 2,550 $20.00

Call Option

(right to buy)

7/15/13 1/17/15 2,320 $7.50

Call Option

(obligation to sell)

7/15/13 1/17/15 2,320 $20.00

Call Option

(right to buy)

7/15/13 1/17/15 2,552 $7.50

Call Option

(obligation to sell)

7/15/13 1/17/15 2,552 $20.00

Call Option

(right to buy)

7/25/13 1/17/15 928 $7.50

Call Option

(obligation to sell)

7/25/13 1/17/15 928 $20.00

Call Option

(right to buy)

9/26/13 1/18/14 2,240 $7.50

Call Option

(obligation to sell)

9/26/13 1/18/14 2,240 $15.00
(2)These option contracts were cancelled on October 1, 2013, through the sale and purchase of options having identical terms, which closing transactions were previously reported in Amendments 3 and 4 to the Statement.

 

Item 7. Material to Be Filed as Exhibits

 

Exhibit 99.1 Joint Filing Agreement by and among the Reporting Persons.

 

The Joint Filing Agreement, executed by and among the Reporting Persons, dated October 4, 2013, which was filed as an exhibit to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on October 4, 2013, is hereby incorporated by reference.

 

 

9
 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: January 20, 2015

 

  RA CAPITAL HEALTHCARE FUND, L.P.
   
 

By: RA Capital Management, LLC

General Partner

   
  By: /s/ Peter Kolchinsky
 

Peter Kolchinsky

Manager

   
   
   
  RA CAPITAL MANAGEMENT, LLC
   
  By: /s/ Peter Kolchinsky
 

Peter Kolchinsky

Manager

   
   
   
  PETER KOLCHINSKY
   
  /s/ Peter Kolchinsky

 

10